Keywords: Shire, arGEN-X. SIMPLE Antibody platform, Rare genetic disorders,

Shire buys rights to arGEN-X technology for rare diseases

Article | 01 March 2012

Dutch/Belgian preclinical stage biotech company arGEN-X, focused on the discovery and development of human monoclonal antibodies from its proprietary ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in